Fill gaps in clinical trial data by generating missing modalities; Reduce assay costs by predicting profiles from routine data; Enable rare disease research through synthesized data types; Accelerate biomarker discovery with imputed molecular markers
Founder/CTO
Strand AI offers a range of services focused on multimodal patient datasets to support life sciences teams in building biological models. Their main product offerings include:
1000 Genomes VariantFormer Dataset: This dataset provides comprehensive genomic information that can be utilized for various research purposes, particularly in understanding genetic variations.
Multimodal Data Synthesis for Clinical Trials: Strand AI's technology addresses the challenge of acquiring diverse data modalities, which are often expensive and invasive. They help fill gaps in clinical trial data by generating missing modalities, allowing researchers to recover insights from incomplete cohorts.
Predictive Modeling: Their platform can predict proteomic or transcriptomic profiles from routine data, enabling researchers to prioritize which assays to validate, thus reducing costs associated with expensive testing.
Support for Rare Disease Research: The company synthesizes lacking data types for small patient populations, facilitating model training and research in rare diseases.
Accelerated Biomarker Discovery: Strand AI's services include imputing unmeasured molecular markers across cohorts, aiding in the identification of predictive signatures that can be crucial for developing new treatments.
These offerings are designed to benefit life sciences research teams, clinical trial coordinators, and researchers focused on rare diseases and biomarker discovery.